Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer

Introduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Metho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Berrin İnanç, Özlem Mermut, Begüm Ökten, Özlem Beşikçi, Ebru Tuncay, Caner Aktaş
Formato:	article
Lenguaje:	EN
Publicado:	Galenos Yayinevi 2021
Materias:	radiotherapy aged survival Medicine R
Acceso en línea:	https://doaj.org/article/88b99b250e4240c0b16fc4e6ae999f87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88b99b250e4240c0b16fc4e6ae999f87
record_format	dspace
spelling	oai:doaj.org-article:88b99b250e4240c0b16fc4e6ae999f872021-11-23T10:25:25ZComparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer2619-97932148-094X10.4274/imj.galenos.2021.29000https://doaj.org/article/88b99b250e4240c0b16fc4e6ae999f872021-11-01T00:00:00Z http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/comparison-of-definitive-radiotherapy-in-the-young/49718 https://doaj.org/toc/2619-9793https://doaj.org/toc/2148-094XIntroduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Methods:A total of 178 patients with prostate cancer treated with definitive RT were retrospectively reviewed. The prognostic factors for survival, metastasis-free survival (MFS), biochemical recurrence-free survival (BFS), and treatment-related toxicities were analyzed.Results:Pretreatment prostate-specific antigen (PSA), last PSA value, and Charlson comorbidity score (5-6) were significantly different between the two groups (p=0.001, p=0.004, and p=0.012, respectively). The elderly showed high pretreatment PSA, last PSA value, and Charlson comorbidity score (5-6). None of the other treatment or patient characteristics differed significantly between the groups. The median follow-up time was 68 months (range: 12-116 months) for the young-elderly. The 5-year overall survival (OS), BFS, and MFS were 86.4%, 91.5%, and 92.8%, respectively, in the young-elderly. Median follow-up time in the elderly patients was 60 months (range: 7-118 months) and 5-year OS, MFS, and BFS rates were 79.6%, 93.1%, and 93.4%, respectively. No statistical difference was found when the OS, BFS, and MFS were evaluated in 5 years in both groups. The multivariate analysis revealed that high radiation doses (76 Gy and ≥78 Gy) and high T-stage (T3-4) was a significant prognostic factor for the BFS in all patients (p=0.013, p=0.007, and p=0.026, respectively). The presence of high-risk patients in the risk stratification was borderline significant for the BFS (p=0.051). Acute hematological toxicity, such as leucopenia (38%), and late toxicity, such as rectal bleeding (10%), were frequently observed in the elderly.Conclusion:No differences were found in the OS, BFS, and MFS between the two groups. High radiation doses and high T-stage was found as a prognostic factor for the BFS in all patients.Berrin İnançÖzlem MermutBegüm ÖktenÖzlem BeşikçiEbru TuncayCaner AktaşGalenos YayineviarticleradiotherapyagedsurvivalMedicineRENİstanbul Medical Journal, Vol 22, Iss 4, Pp 326-331 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	radiotherapy aged survival Medicine R
spellingShingle	radiotherapy aged survival Medicine R Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
description	Introduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Methods:A total of 178 patients with prostate cancer treated with definitive RT were retrospectively reviewed. The prognostic factors for survival, metastasis-free survival (MFS), biochemical recurrence-free survival (BFS), and treatment-related toxicities were analyzed.Results:Pretreatment prostate-specific antigen (PSA), last PSA value, and Charlson comorbidity score (5-6) were significantly different between the two groups (p=0.001, p=0.004, and p=0.012, respectively). The elderly showed high pretreatment PSA, last PSA value, and Charlson comorbidity score (5-6). None of the other treatment or patient characteristics differed significantly between the groups. The median follow-up time was 68 months (range: 12-116 months) for the young-elderly. The 5-year overall survival (OS), BFS, and MFS were 86.4%, 91.5%, and 92.8%, respectively, in the young-elderly. Median follow-up time in the elderly patients was 60 months (range: 7-118 months) and 5-year OS, MFS, and BFS rates were 79.6%, 93.1%, and 93.4%, respectively. No statistical difference was found when the OS, BFS, and MFS were evaluated in 5 years in both groups. The multivariate analysis revealed that high radiation doses (76 Gy and ≥78 Gy) and high T-stage (T3-4) was a significant prognostic factor for the BFS in all patients (p=0.013, p=0.007, and p=0.026, respectively). The presence of high-risk patients in the risk stratification was borderline significant for the BFS (p=0.051). Acute hematological toxicity, such as leucopenia (38%), and late toxicity, such as rectal bleeding (10%), were frequently observed in the elderly.Conclusion:No differences were found in the OS, BFS, and MFS between the two groups. High radiation doses and high T-stage was found as a prognostic factor for the BFS in all patients.
format	article
author	Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş
author_facet	Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş
author_sort	Berrin İnanç
title	Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
title_short	Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
title_full	Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
title_fullStr	Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
title_full_unstemmed	Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
title_sort	comparison of definitive radiotherapy in the young-elderly and elderly with clinical localized prostate cancer
publisher	Galenos Yayinevi
publishDate	2021
url	https://doaj.org/article/88b99b250e4240c0b16fc4e6ae999f87
work_keys_str_mv	AT berrininanc comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ozlemmermut comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT begumokten comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ozlembesikci comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ebrutuncay comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT caneraktas comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer
_version_	1718416776794996736

Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer

Ejemplares similares